30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

DiscGenics' U.S. Clinical Study of Cell Therapy for Disc Degeneration Passes Halfway Mark -

The first 30 patients received treatment in DiscGenics' first-in-human U.S. clinical study of IDCT allogeneic injectable disc cell therapy for mild to moderate degenerative disc disease. The prospective, randomized, double-blinded, vehicle- and placebo-controlled clinical study will enroll 60 patients in 14 centers across 12 states in the U.S. IDCT is being evaluated under an Investigational New Drug allowance and will be regulated as a drug/biologic through a therapeutics biologics license application. IDCT uses discogenic cells to yield a potentially regenerative treatment for disc disease. Preclinical studies have shown that IDCT normalized disc architecture and restored disc height in animal models. If the same can be shown in humans, it could present an alternative to non-restorative, late-stage surgeries. (DiscGenics, 9/16/19)